Since the outbreak of Corona Virus Disease 2019 (COVID-19), it has rapidly swept through most countries around the world and continues to spread. As of February 28, 2022, the official WHO data shows that the new crown epidemic has claimed more than 5.96 million lives and infected nearly 435.59 million people. Whether it is the detection, prevention or treatment of the new crown, countries are under enormous pressure.
In response to the new crown epidemic, the long-term solution is to successfully develop a safe and effective vaccine. On January 6, local time, the WHO held a routine press conference on the new crown pneumonia epidemic. Bruce Aylward, senior adviser to the WHO Director-General, said that the "COVID-19 Vaccine Implementation Plan" has delivered more than 180 million doses of China Kexing and Sinopharm vaccines to 49 countries, accounting for more than 180 million doses of the "New Coronary Pneumonia Vaccine Implementation Plan" distributed. Vaccines account for nearly 20% of the total and are an important part of boosting immunity and saving lives worldwide.
In the process of vaccine development and marketing, the most important indicator to evaluate the effectiveness of the new crown vaccine is the content of neutralizing antibodies in the subject. Patients with new coronary pneumonia will produce anti-viral antibodies a few days or a week after being infected. Among them, neutralizing antibodies, as antibodies with anti-viral activity, only account for a small part of anti-viral antibodies. Neutralizing antibodies can recognize virus surface proteins. Block the virus from binding to specific receptors on the cell surface, thereby preventing the virus from continuing to invade human cells.
In addition to vaccines, the screening of effective antibody drugs from neutralizing antibodies is also regarded as a powerful weapon against the new coronavirus. Unlike vaccines, which rely on the body's own ability to generate an adequate immune response to prevent disease, antibody drugs work more quickly and provide an immediate immune response. In addition, antibody drugs also have the advantages of high accessibility and rapid subsequent large-scale production.
It can be seen that neutralizing antibodies play an extremely important role in the development of new crown vaccines and antibody drugs. How to quickly detect neutralizing antibodies has become the top priority in accelerating the global anti-epidemic process. The related neutralizing antibody detection and verification, in addition to being routinely used to assess the human body's immunity to the new coronavirus, also played an important "hidden function" in the process of vaccine and antibody drug development.